505 Results

People

  1. Herr
    Herr
  2. Bochner
    Bochner
  3. Dalbagni
    Dalbagni
  4. Donat
    Donat
  5. Cordon-Cardo
    Cordon-Cardo
  6. Reuter
    Reuter
  7. Al-Ahmadie
    Al-Ahmadie
  8. Bajorin
    Bajorin
  9. Rosenberg
    Rosenberg
  10. Fair
    Fair

Groups

  1. Surgery (296)
  2. Urology (286)
  3. Department of Medicine (97)
  4. Solid Tumor Oncology Division (94)
  5. Department of Pathology and Laboratory Medicine (89)
  6. Genitourinary Oncology Service (88)
  7. Epidemiology and Biostatistics (51)
  8. Population Sciences Research Program (37)
  9. Survivorship Research (36)
  10. GSK Faculty (30)
  1. "urinary bladder neoplasms"
Formats
  1. Journal Article (468)
  2. Review (23)
  3. Editorial (5)
  4. Conference Paper (3)
  5. Guidelines (3)
  6. Book Section (2)
  7. Correspondence (1)
Groups
  1. Surgery (296)
  2. Urology (286)
  3. Department of Medicine (97)
  4. Solid Tumor Oncology Division (94)
  5. Department of Pathology and Laboratory Medicine (89)
  6. Genitourinary Oncology Service (88)

More Groups

People
  1. Harry Herr (172)
  2. Bernard Bochner (92)
  3. Guido Dalbagni (89)
  4. Sherri Donat (66)
  5. Carlos Cordon-Cardo (62)
  6. Victor Reuter (51)

More People

Years
  1. 2025 (6)
  2. 2024 (21)
  3. 2023 (34)
  4. 2022 (25)
  5. 2021 (5)
  6. 2020 (5)

More Years

Publications
  1. Journal of Urology (99)
  2. European Urology (35)
  3. BJU International (29)
  4. Cancer (23)
  5. Urology (23)
  6. Clinical Cancer Research (20)

More Publications

Publishers
  1. Elsevier Science, Inc. (166)
  2. Wiley Blackwell (61)
  3. Elsevier Inc. (41)
  4. American Association for Cancer Research (39)
  5. Nature Publishing Group (22)
  6. Springer (20)

More Publishers

Results (505)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma
    Journal Article

    Rosenberg, J. E.; Powles, T.; Sonpavde, G. P.; Loriot, Y.; Duran, I.; Lee, J. L.; Matsubara, N.; Vulsteke, C.; Castellano, D.; Mamtani, R.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Feasibility and tissue concordance of genomic sequencing of urinary cytology in upper tract urothelial carcinoma
    Journal Article

    Katims, A. B.; Gaffney, C.; Firouzi, S.; Yip, W.; Aulitzky, A.; Pietzak, E. J.; Donat, S. M.; Bochner, B. H.; Donahue, T. F.; Herr, H. W.; more...
    Urologic Oncology: Seminars and Original Investigations (2023)

    Fulltext@MSK | Save
  • Clinical and genomic landscape of FGFR3-altered urothelial carcinoma and treatment outcomes with erdafitinib: A real-world experience
    Journal Article

    Guercio, B. J.; Sarfaty, M.; Teo, M. Y.; Ratna, N.; Duzgol, C.; Funt, S. A.; Lee, C. H.; Aggen, D. H.; Regazzi, A. M.; Chen, Z.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Evaluating residual tumor after neoadjuvant chemotherapy for muscle-invasive urothelial bladder cancer: Diagnostic performance and outcomes using biparametric vs. multiparametric MRI
    Journal Article

    Woo, S.; Becker, A. S.; Das, J. P.; Ghafoor, S.; Arita, Y.; Benfante, N.; Gangai, N.; Teo, M. Y.; Goh, A. C.; Vargas, H. A.
    Cancer Imaging (2023)

    Fulltext@MSK | Save
  • Checkpoint inhibitors in urothelial carcinoma—Future directions and biomarker selection
    Review

    Meeks, J. J.; Black, P. C.; Galsky, M.; Grivas, P.; Hahn, N. M.; Hussain, S. A.; Milowsky, M. I.; Steinberg, G. D.; Svatek, R. S.; Rosenberg, J. E.
    European Urology (2023)

    Fulltext@MSK | Save
  • IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against bladder cancer
    Journal Article

    Wong, J. L.; Smith, P.; Angulo-Lozano, J.; Ranti, D.; Bochner, B. H.; Sfakianos, J. P.; Horowitz, A.; Ravetch, J. V.; Knorr, D. A.
    Proceedings of the National Academy of Sciences of the United States of America (2023)

    Fulltext@MSK | Save
  • Bladder cancer carcinogens: Opportunities for risk reduction
    Review

    Gaffney, C. D.; Katims, A.; D'Souza, N.; Bjurlin, M. A.; Matulewicz, R. S.
    European Urology Focus (2023)

    Fulltext@MSK | Save
  • Background and update for ECOG-ACRIN EA8212: A randomized phase 3 trial of intravesical bacillus Calmette-Guérin (BCG) versus intravesical docetaxel and gemcitabine treatment in BCG-naïve high-grade non–muscle-invasive bladder cancer (BRIDGE)
    Review

    Kates, M.; Chu, X.; Hahn, N.; Pietzak, E.; Smith, A.; Shevrin, D. H.; Crispen, P.; Williams, S. B.; Daneshmand, S.; Packiam, V. T.; more...
    European Urology Focus (2023)

    Fulltext@MSK | Save
  • Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): An international, single-arm, phase 2 study
    Journal Article

    Pant, S.; Schuler, M.; Iyer, G.; Witt, O.; Doi, T.; Qin, S.; Tabernero, J.; Reardon, D. A.; Massard, C.; Minchom, A.; more...
    Lancet Oncology (2023)

    Fulltext@MSK | Save
  • Health-related quality of life after robotic-assisted vs open radical cystectomy: Analysis of a randomized trial. Reply
    Correspondence

    Clements, M. B.; Beech, B. B.; Atkinson, T. M.; Dalbagni, G. M.; Li, Y.; Vickers, A. J.; Herr, H. W.; Donat, S. M.; Sjoberg, D. D.; Tin, A. L.; more...
    Journal of Urology (2023)

    Fulltext@MSK | Save